Shorena Janelidze

Jul 28, 2024 | jamanetwork.com | Shorena Janelidze |Gemma Salvadó |Suzanne Schindler |Sebastian Palmqvist

Key PointsQuestion  Which plasma biomarkers are useful to predict future development of Alzheimer disease (AD)–related β-amyloid (Aβ) pathology in cognitively unimpaired individuals (CU) with low brain Aβ levels?

Jun 13, 2024 | medrxiv.org | Rik Ossenkoppele |Gemma Salvadó |Shorena Janelidze |Alexa Pichet Binette

R.O. has received research support from Avid Radiopharmaceuticals, Janssen Research & Development, Roche, Quanterix and Optina Diagnostics. He has given lectures in symposia sponsored by GE Healthcare and serves on advisory boards for Asceneuron and Bristol Myers Squibb. SP has acquired research support (for the institution) from ki elements / ADDF and Avid. In the past 2 years, he has received consultancy/speaker fees from Bioartic, Biogen, Esai, Lilly, and Roche.

Jul 18, 2023 | nature.com | Sebastian Palmqvist |Shorena Janelidze |Simone Baiardi |Oskar Hansson

AbstractThere is poor knowledge about the clinical effects of Lewy body (LB) pathology in patients with cognitive impairment, especially when coexisting with Alzheimer’s disease (AD) pathology (amyloid-β and tau). Using a seed amplification assay, we analyzed cerebrospinal fluid for misfolded LB-associated α-synuclein in 883 memory clinic patients with mild cognitive impairment or dementia from the BioFINDER study.